Afexa Life Sciences Inc.

Afexa Life Sciences Inc.

March 01, 2005 11:51 ET

COLD-fX® to be Studied as New Way to Protect Seniors from Influenza in Canadian Nursing Homes




MARCH 1, 2005 - 11:51 ET

COLD-fX'R' to be Studied as New Way to Protect Seniors
from Influenza in Canadian Nursing Homes

EDMONTON, ALBERTA--(CCNMatthews - March 1, 2005) - CV Technologies Inc.
(CVT) (TSX VENTURE:CVQ) today announces the beginning of a unique
partnership project to investigate the potential use of COLD-fX® as a
"standard of care" for the prevention of upper respiratory infections in
Canadian nursing homes. The first phase of the project is a pilot
clinical study conducted among residents in up to four Edmonton area
continuing care facilities to examine tolerability.

Health Canada's weekly "Flu Watch" report indicates that so far this
winter in Canada there has been an average of 3 flu outbreaks a day in
long term care facilities and retirement lodges. Government statistics
indicate that more than 700 people, mostly seniors, die from flu related
complications in North America each week during the winter months.
Influenza is the fourth leading cause of death in people over 65.

Capital Health and the University of Alberta have conducted two clinical
trials on COLD-fX® involving healthy adults in the Edmonton area for
both prevention and treatment of upper respiratory tract infections.
Capital Health and CVT have joined in a unique partnership with the Good
Samaritan Society as part of the new study which aims to enroll 200
residents over the next four months. Recruitment has already begun.

Capital Health Medical Officer of Health, Dr. Gerry Predy, who is also
Director of the Northern Alberta Vaccine Trials and Evaluation Centre
says, "Discovering ways to reduce the impact of flu on seniors is an
important public health issue. While flu shots provide seniors with
vital protection given their vulnerability, we're always looking for
ways to give them additional protection. I'm hopeful that COLD-fX®
might be beneficial in conjunction with flu shots to help our seniors'

Dr. Elaine Stokes, a Geriatrician and Vice-President of Medical/Clinical
Services for the Good Samaritan Society echoes that view. She says, "Flu
outbreaks in continuing care facilities are constantly and diligently
monitored. When an infection is suspected, the centre is unable to admit
new residents transferring from a hospital, resulting in a prolonged
stay in a much more expensive hospital bed. This creates a backlog and
generates significant pressure on the entire health care system."

While influenza shots are very helpful in protecting seniors, the
spectrum of other protection is limited to only certain types of
influenza strains, providing no protection against other respiratory
viruses. The current pharmaceutical options are limited in supply, as
well as in safety and efficacy. In addition, the threat of a major
influenza pandemic has escalated with the continuing avian influenza
outbreak in Asia.

CVT President, CEO & Chief Scientific Officer, Dr. Jacqueline Shan said,
previous studies involving more than 700 participants, including two
FDA-regulated studies in seniors, provided a good indication of the
safety and efficacy of COLD-fX® for upper respiratory infections. "We
hope this first phase of a study to explore COLD-fX® as a 'standard of
care' in Canadian nursing homes will provide us with important clinical
data in the search for ways to provide flu protection for this important
'at risk' segment of society."

Each participant will be administered two capsules of COLD-fX® per day
for a period of 4 months. The safety of COLD-fX® use will be
investigated and the rate of influenza-like illness will be compared
with other continuing care facilities. The current study has received
approval from both the Capital Health/University of Alberta Research
Ethics Board, as well as Health Canada's Natural Health Products

COLD-fX® is a proprietary natural health compound - a result of a
decade of research and development by a team of 25 scientists. In lab
and clinical studies - many published in medical journals - it has been
shown to have an excellent safety profile with no adverse side effects.


Capital Health in Edmonton is Canada's largest academic health region,
providing complete health services to 1 million residents in the cities
of Edmonton, Fort Saskatchewan, Leduc, Spruce Grove and St. Albert, and
the counties of Leduc, Parkland, Strathcona and Sturgeon and part of
Yellowhead County. Capital Health serves a total of 1.6 million people
across central and northern Alberta, providing specialized services such
as trauma and burn treatment, organ transplants and high-risk obstetrics.


The Good Samaritan Society (A Lutheran Social Service Organization) has
over 55 years experience in providing continuing care, assisted living
and other specialized health care services and facilities in an
innovative and caring environment. It is one of the largest voluntary
health care providers in Canada. The Society is a registered charity,
governed by a volunteer Board of Directors, and has facilities in
Edmonton, Stony Plain, Spruce Grove, Evansburg, Lethbridge, Lacombe,
Rocky Mountain House, Pincher Creek, Hinton, Kelowna and Penticton.


CV Technologies is a biotechnology company founded in 1992. It aims to
become a global leader in the development, distribution, marketing and
selling of safe and effective natural health products for disease
prevention and health maintenance. CVT's lead product - COLD-fX®,
strengthens the immune system and is widely used as a leading anti-cold,
anti-flu treatment.

This news release contains forward-looking statements that involve risks
and uncertainties, which may cause actual results to differ materially
from the statements made. For this purpose, any statements that are
contained herein that are not statements of historical fact may be
deemed to be forward-looking statements. Without limiting the foregoing,
the words "believes", "anticipates", "plans", "intends", "expects" and
similar expressions are intended to identify forward-looking statements.
Such risks and uncertainties include, but are not limited to, the need
for capital, changing market conditions, completion of clinical trials,
patient enrolment rates, uncertainty of pre-clinical, retrospective and
early clinical trial results, the establishment of manufacturing
processes and new corporate alliances, the timely development,
regulatory approval and market acceptance of the Company's products, and
other risks detailed from time to time in the Company's filings with
Canadian securities authorities.


Contact Information